3 Big Drugs to be launched on the Market in 1Q11 .Market cap of 7 million$ is a big joke .
Get in now before the stock gets Discovered !!! Easy money at this level .
Puramed (PMBS.PK)
Market Cap: 7,2 M$
Cash : 5 M$ agreement with Lincoln capital Fund (june 2010)
Price 0,51 $
Shares Out: 14.1 M ...( 12 million shares held by insiders )
Low Float : 5 M
How many products does PuraMed BioScience have in progress?
LipiGesic M for the relief of migraine headaches is the first PuraMed product that will be introduced to the market. Following its entrance into the market, two other products, LipiGesic PM for insomnia and LipiGesic H for tension headaches, will be developed and introduced. There are also product formulations for relief from canker sores, restless-leg syndrome, nighttime-reflux disorders, smoking cessation, and weight loss that will soon follow.
PuraMed was established to capture two unique opportunities. The first is to build a substantial and profitable business, rapidly, beginning with three products developed by its founders: LipiGesic™ M (for acute relief of migraine headaches), LipiGesic™ H(for acute relief of tension headaches) and PuraMed™ PM (for insomnia). Each of these is effective and addresses a very large OTC consumer market, collectively well over $2 billion in the U.S. Each product will be unique in its class.
The second, longer term, opportunity is to establish a leadership position in the highly fragmented OTC natural and alternative health remedy market by introducing a “new kind of product line.” Our product line will consist of ‘alternative’ remedies for common ailments, marketed to the masses. Most consumers want products that are, first of all, effective and safe. By applying hard science to ‘natural’ products, management believes it is possible to build a line wherein each product delivers better performance with fewer side effects than its chemical counterparts. With effective marketing, these products will be embraced by the majority, many of whom prefer ‘natural’ alternatives, provided there is no need to sacrifice performance or convenience.
PuraMed BioScience, Inc will enter the OTC (Over-The-Counter) medicine marketplace by employing direct to consumer marketing and applying broad retail distribution and effective marketing to several unique products now developed and known to be effective. The company intends to launch its first two retail products within six months and leverage that success to ultimately become a leader in the OTC medicine marketplace.
